IN8bio Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights - Reported 100% of Acute Myeloid Leukemia (AML) patients treated in INB-100 remain in complete remission (CR) at the 2024 European Hematology Association Congress and received FDA guidance for a future INB-100 registrational trial - INB-100 trial currently expanding enrollment up to approximately 25 patients at the recommended Phase 2 dose (RP2D) along with the potential to add additional centers and a prospective parallel o ...

Reported 100% of Acute Myeloid Leukemia (AML) patients treated in INB-100 remain in complete remission (CR) at the 2024 European Hematology Association Congress and received FDA guidance for a future INB-100 registrational trialINB-100 trial currently expanding enrollment up to approximately 25 patients at the recommended Phase 2 dose (RP2D) along with the potential to add additional centers and a prospective parallel observational cohort as a controlClosed private placement for net proceeds of $11.6 Millio ...

Core Insights - IN8bio is prioritizing its clinical program for INB-100 in acute myeloid leukemia (AML), reporting a 100% progression-free survival rate as of August 30, 2024 [1][8] - The company is suspending enrollment in the Phase 2 clinical trial of INB-400 for newly diagnosed glioblastoma (GBM) while continuing to monitor existing patients [2][4] - A workforce reduction of approximately 49% is being implemented to optimize resource allocation and preserve cash resources [2][10] Clinical Programs - INB-100 for AML is the primary focus, with plans to enroll approximately 25 additional patients in the expansion cohort, targeting completion in the first half of 2025 [6] - The company aims to affirm the positive clinical data for INB-100, which has shown a 100% relapse-free survival rate after a median follow-up of 18.7 months [8][7] - INB-200 has completed patient treatment, while enrollment in INB-400 is on hold as the company seeks partnership opportunities [4][9] Financial and Operational Strategy - The workforce reduction is expected to be completed in the third quarter of 2024, with one-time costs of approximately $0.3 million primarily related to severance [10] - The company is focusing on key milestones to generate near-term interest and value creation, particularly through the INB-100 program [5] - IN8bio had a Type B meeting with the FDA, receiving guidance on advancing INB-100 as a post-transplant maintenance therapy [7]

Received FDA guidance on the registrational path for INB-100 in acute myeloid leukemia (AML), an investigational allogeneic gamma-delta T cell therapy, with IND submission anticipated in Q1 2025. Early clinical data from investigator sponsored trials demonstrates prolonged relapse-free survival across both AML and glioblastoma (GBM) programs, compared to current standard-of-care, with both programs advancing to Phase 2 clinical development. Solidifying position as a leader in gamma-delta T cell therapy for ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39692 IN8BIO, INC. (Exact name of Registrant as specified in its Charter) Delaware 82-5462585 (State or other jurisdiction of in ...

302406282 v3 IN8bio Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights - Presented positive Phase 1 data showing 100% 1-year complete remission (CR) in evaluable patients with hematologic malignancies including acute myelogenous leukemia (AML) for INB-100 at the European Hematology Association (EHA) 2024 Congress - Continues to be an industry leader in the manufacturing and the clinical advancement of gamma-delta T cells for the treatment of solid and hematologic cancers - Demonst ...

NEW YORK, June 24, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced that William Ho, CEO and Co-founder, will participate in a fireside chat during the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference on Tuesday, June 25, 2024 at 2:30 p.m. ET. About IN8bio IN8bio has initiated a Phase 2 trial of INB-400 in GBM in the United States and has two ongoing Phase 1 trials in ...

100% of treated leukemia patients (n=10/10) achieved durable complete remission (CR) at 1-year, including high-risk and relapsed acute myeloid leukemia (AML) patients who had previously failed multiple lines of therapy, including CAR-T. Data continue to show long-term in vivo expansion and persistence of allogeneic gamma-delta T cells 365 days following a single administration, demonstrating first-ever durable persistence and expansion of an allogeneic cellular therapy. The Company will host a conference ca ...

100% of treated leukemia patients (n=10/10) achieved durable complete remission (CR) at 1-year, including high-risk and relapsed acute myeloid leukemia (AML) patients who had previously failed multiple lines of therapy, including CAR-T. The Company will host a conference call at 4:15 pm ET. Use this link to participate. A listen-only version of the webcast is available here. NEW YORK, June 13, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovat ...

92% of evaluable patients treated with INB-200 for glioblastoma exceeded a median progression-free survival (PFS) of seven months achieved with the standard-of-care regimen (Stupp regimen) Majority of fully dosed patients exceeded the expected median PFS based on age and tumor status; one patient from Cohort 2 remains alive and progression free at almost three years Radiologic evaluation indicative of "treatment effect" including changes in MRI enhancement and resolution of mid-line shift NEW YORK, June 03, ...